Aluna

Executive Summary

Aluna is a San Francisco-based digital health company specializing in respiratory care. Its core offering is an FDA-cleared, portable spirometer paired with a companion mobile app, designed for patients with chronic lung conditions such as asthma and cystic fibrosis. The device measures key lung function metrics like FEV1 and PEF, while the app enables symptom tracking, medication logging, and seamless data sharing with healthcare providers. Additionally, Aluna serves as a remote monitoring platform for clinical trials, providing real-time, accurate spirometry data collection to support drug development and research. Founded in 2014, the company operates in the high-growth digital health and respiratory care segments, addressing the significant unmet need for at-home, patient-friendly lung function monitoring. Aluna's value proposition lies in its ability to improve patient outcomes through continuous monitoring, reduce hospitalizations, and enhance clinical trial efficiency. The company is well-positioned to benefit from the increasing adoption of remote patient monitoring and decentralized clinical trials. Key risks include competition from other digital spirometry devices, regulatory challenges, and the need to secure broad insurance reimbursement. Despite these, Aluna's FDA clearance and established platform provide a strong foundation for growth. The company's focus on respiratory diseases, which affect millions globally, and its utility in both clinical and research settings underpin its potential for market penetration.

Upcoming Catalysts (preview)

• Q4 2025Next-generation device launch or FDA clearance for expanded indications70% success
• Q3 2025Major partnership with a pharmaceutical company for remote monitoring in respiratory clinical trials60% success
• Q2 2026Reimbursement approval from CMS or private insurers for home spirometry monitoring50% success